Advertisement
Canada markets close in 3 hours 6 minutes
  • S&P/TSX

    22,178.78
    +71.70 (+0.32%)
     
  • S&P 500

    5,251.74
    +3.25 (+0.06%)
     
  • DOW

    39,765.92
    +5.84 (+0.01%)
     
  • CAD/USD

    0.7389
    +0.0017 (+0.23%)
     
  • CRUDE OIL

    82.84
    +1.49 (+1.83%)
     
  • Bitcoin CAD

    95,693.83
    +2,329.88 (+2.50%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,244.30
    +31.60 (+1.43%)
     
  • RUSSELL 2000

    2,129.58
    +15.23 (+0.72%)
     
  • 10-Yr Bond

    4.1930
    -0.0030 (-0.07%)
     
  • NASDAQ

    16,384.38
    -15.14 (-0.09%)
     
  • VOLATILITY

    12.97
    +0.19 (+1.49%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6839
    +0.0034 (+0.50%)
     

Ceapro Announces Results of 2020 Shareholders’ Meeting

EDMONTON, Alberta, June 22, 2020 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its Annual General and Special Meeting of Shareholders held on June 19, 2020 as per the following results:

Nominee

Votes for

Votes withheld

% of votes cast

FOR

WITHELD

Glenn Rourke

12,579,840

3,594,034

77.78%

22.22%

Donald J. Oborowsky

15,455,223

718,651

96.56%

4.44%

John Zupancic

14,166,683

2,007,191

87.59%

12.41%

Gilles Gagnon

14,037,480

2,136,394

86.79%

13.21%

Dr. William Li

14,607,183

1,566,691

90.31%

9.69%

Dr. Ulrich Kosciessa

15,992,583

181,291

98.88%

1.12%

All other matters at the Shareholders' meeting, namely the appointment of auditors and the re-approval and ratification of the Company’s Stock Option Plan, as proposed in the Company’s information circular dated April 30, 2020, were also approved by shareholders.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

ADVERTISEMENT

For more information on Ceapro, please visit the Company’s website at www.ceapro.com.

For more information contact:

Jenene Thomas
JTC Team, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247
E: czo@jtcir.com

Issuer:

Gilles R. Gagnon, M.Sc., MBA
President & CEO
T: 780-421-4555

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release